Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Puma Biotechnology, Inc.
NCT07109154 · Lung Neoplasms
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT03429036 · Hearing Disorder, Oral Mucosal Disease, and more
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
NCT07222800 · Intestinal Neoplasms, Gastrointestinal Neoplasms, and more
University of Colorado Hospital
Aurora, Colorado
Midwestern Regional Medical Center
Zion, Illinois
Louisiana State University
Shreveport, Louisiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions